uniQure Reports Completion of Patient Enrollment in the First Two Cohorts of P-I/II Trial for AMT-130 to Treat Huntington’s Disease
Shots:
- The company has completed patient enrollment in the 1st two cohorts of the P-I/II trial to evaluate the safety, tolerability & POC of AMT-130 in 26 patients with HD. The trial consists of 12mos. period based on long-term follow-up for 5yrs.
- The 1st dose cohort comprised of 10 patients in which 6 patients received AMT-130 & 4 patients received imitation surgery. In the 2nd dose cohort, 10 out of 16 patients received AMT-130 & 6 received imitation surgery
- The clinical update from the 12mos. interim analysis of the 10 patients in the 1st cohort is expected in Q2’22 including safety, mHTT & NfL. The company plans to initiate enrollment of EU trial of AMT-130 & initiate a 3rd patient cohort in the US
Ref: uniQure | Image: uniQure
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
